Amoéba
Develops natural microbiological solutions to manage bacterial and fungal risks.
ALMIB | PA
Overview
Corporate Details
- ISIN(s):
- FR0011051598 (+2 more)
- LEI:
- 9695005QNE7C8Z0LXU64
- Country:
- France
- Address:
- 38 AVENUE DES FRERES MONTGOLFIER, 69680 CHASSIEU
- Website:
- https://amoeba-nature.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other chemical products
Description
Amoéba is a biotechnology company that develops natural microbiological solutions for managing bacterial and fungal risks. The company's core technology is based on the patented use of the amoeba *Willaertia magna* C2c Maky and its biocidal properties. Its primary focus is on agricultural biocontrol, offering a biofungicide derived from a mechanically lysed amoeba. This product targets plant diseases such as mildews, rusts, and powdery mildew, providing a biological alternative to chemical treatments. Amoéba has also developed applications for its technology in the treatment of bacterial risk in industrial water systems, on surfaces, and for chronic wounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2022-11-03 08:45 |
AMOEBA : L'US EPA approuve la solution de biocontrôle pour un usage en agricult…
|
French | PDF • 263.9 KB | ||
| 2022-11-03 08:45 |
AMOEBA: US EPA approves Amoeba's biocontrol solution for agricultural use
|
English | PDF • 252.3 KB | ||
| 2022-10-20 17:45 |
Amoéba : année record en nombre et en performance des essais en champ
|
French | PDF • 289.8 KB | ||
| 2022-10-20 17:45 |
Amoéba: a record year for the number and performance of field trials
|
English | PDF • 270.8 KB | ||
| 2022-10-19 17:45 |
Amoéba retire son dossier biocide au Canada pour concentrer ses ressources sur …
|
French | PDF • 250.4 KB | ||
| 2022-10-19 17:45 |
Amoeba withdraws its biocide file in Canada to focus its resources on strategic…
|
English | PDF • 241.8 KB | ||
| 2022-10-18 17:45 |
Amoéba : publication d’un article scientifique sur l’efficacité de ses produits…
|
French | PDF • 268.4 KB | ||
| 2022-10-18 17:45 |
Amoéba: publication of a scientific article concerning the efficacy of its bioc…
|
English | PDF • 255.2 KB | ||
| 2022-10-12 13:15 |
AMOEBA: US EPA approves tolerance exemption for the biocontrol active substance…
|
English | PDF • 243.3 KB | ||
| 2022-10-12 13:15 |
AMOEBA : L'US EPA approuve l’exemption de résidu de la substance active de bioc…
|
French | PDF • 265.7 KB | ||
| 2022-10-03 18:00 |
AMOEBA : Déclaration du nombre de droits de vote et d'actions
|
French | PDF • 222.5 KB | ||
| 2022-10-03 17:45 |
AMOEBA : 2022 Interim Financial Report
|
English | PDF • 223.5 KB | ||
| 2022-10-03 17:45 |
AMOEBA : Rapport financier semestriel 2022
|
French | PDF • 814.7 KB | ||
| 2022-09-29 18:00 |
Amoéba annonce ses résultats semestriels 2022
|
French | PDF • 351.8 KB | ||
| 2022-09-29 18:00 |
Amoéba announces its half-year results for 2022
|
English | PDF • 322.6 KB |
Automate Your Workflow. Get a real-time feed of all Amoéba filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Amoéba
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Amoéba via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-30 | N/A | Other | Buy | 6,300 | 3,609.90 EUR |
| 2024-08-29 | N/A | Other | Sell | 5,500 | 3,564.00 EUR |
| 2024-08-28 | N/A | Other | Buy | 3,200 | 1,782.08 EUR |
| 2024-08-27 | N/A | Other | Buy | 20,049 | 11,231.45 EUR |
| 2024-08-26 | N/A | Other | Buy | 31,107 | 17,441.69 EUR |
| 2024-08-22 | N/A | Other | Buy | 2,255 | 1,298.88 EUR |
| 2024-08-20 | N/A | Other | Buy | 16,664 | 8,838.59 EUR |
| 2024-08-19 | N/A | Other | Buy | 13,390 | 6,795.43 EUR |
| 2024-08-16 | N/A | Other | Buy | 6,745 | 3,468.28 EUR |
| 2024-08-09 | N/A | Other | Buy | 40,748 | 21,559.77 EUR |
Peer Companies
